Clinical trials: Anterior Uveitis
- Condition Anterior Uveitis
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Behçet Disease
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD)…
- Trial name
- BEAN (NCT04528082)
- Testing
- Apremilast
- Where
- 27 sites in France, Greece and 6 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Uveitis, Anterior
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment…
- Trial name
- NCT00694135
- Testing
- EGP-437 1.6 mA-min at 0.4 with EyeGate® II System, EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System, EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System
- Where
- 19 sites in United States, India
- Volunteers
- 40 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with clinically quiescent non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404742)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 232 people
- Sponsor
- Lux Biosciences, Inc.
Behcet's Disease, Behcet Syndrome
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of TA-650 in patients with Behcet's disease ( BD ) with special lesions after the administration of TA-650 at a dosage of 5 mg/kg in weeks 0, 2…
- Conditions
- Behcet's Disease, Behcet Syndrome, Neuro-Behcet's Disease
- Trial name
- NCT01532570
- Testing
- TA-650
- Where
- 6 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Tanabe Pharma Corporation
Uveitis
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear…
- Trial name
- NCT04088409
- Testing
- Baricitinib, Adalimumab
- Where
- 20 sites in France, Germany and 3 more
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Non-infectious Anterior Uveitis, Uveitic Glaucoma
TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma
- Trial name
- NCT05042609
- Testing
- TRS01, FDA approved steroid eye drop (masked)
- Where
- 30 sites in United States, France and 1 more
- Volunteers
- 142 people
- Sponsor
- Tarsier Pharma
Behcet's Disease
Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease. 1.
- Trial name
- NCT01960790
- Volunteers
- 473 people
- Sponsor
- AbbVie
Uveitis, Panuveitis
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis
The purpose of this phase 3 open-labeled study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of severe uveitis.
- Trial name
- NCT00407056
- Testing
- Difluprednate Ophthalmic Emulsion
- Volunteers
- 20 people
- Sponsor
- Sirion Therapeutics, Inc.
Anterior Uveitis, Panuveitis
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
The purpose of this phase 3 confirmatory study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of treatment of uveitis.
- Trial name
- NCT00406887
- Testing
- Difluprednate Ophthalmic Emulsion
- Volunteers
- 140 people
- Sponsor
- Sirion Therapeutics, Inc.
Behçet's Disease, Juvenile Psoriatic Arthritis
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic…
- Trial name
- NCT05767047
- Testing
- Apremilast
- Where
- 7 sites in Greece, Israel and 2 more
- Volunteers
- 48 people
- Sponsor
- Amgen
Anterior Uveitis
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- NCT01505088
- Testing
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution
- Where
- 39 sites in United States
- Volunteers
- 193 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Anterior Uveitis
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- EGP-437-006 (NCT02517619)
- Testing
- Dexamethasone Phosphate Ophthalmic Solution, Prednisolone Acetate Ophthalmic (1%)
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Endogenous Anterior Uveitis
Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
The purpose of this study was to demonstrate that difluprednate 0.05% (Durezol) dosed 4 times daily is noninferior to prednisolone 1% (Pred Forte) dosed 8 times daily for the treatment of endogenous anterior uveitis.
- Trial name
- NCT01201798
- Testing
- Difluprednate 0.05% ophthalmic emulsion, Prednisolone acetate 1.0% ophthalmic suspension
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Uveitis, Anterior, Panuveitis
A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
- Trial name
- LUMINATE (NCT00404885)
- Testing
- LX211
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 108 people
- Sponsor
- Lux Biosciences, Inc.
Uveitis, Posterior, Uveitis, Intermediate
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- LUMINATE (NCT00404612)
- Testing
- LX211
- Where
- 41 sites in United States, Austria and 5 more
- Volunteers
- 218 people
- Sponsor
- Lux Biosciences, Inc.